Adaptive Biotechnologies (NASDAQ:ADPT) CEO Chad Robins Sells 321,324 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CEO Chad Robins sold 321,324 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $25.08, for a total value of $8,058,805.92. Following the completion of the sale, the chief executive officer directly owned 2,180,518 shares in the company, valued at $54,687,391.44. This represents a 12.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Adaptive Biotechnologies Stock Performance

ADPT stock opened at $25.49 on Thursday. Adaptive Biotechnologies Corporation has a 1 year low of $12.00 and a 1 year high of $26.16. The stock has a market capitalization of $4.07 billion, a price-to-earnings ratio of -62.17 and a beta of 2.08. The company has a debt-to-equity ratio of 2.22, a quick ratio of 4.68 and a current ratio of 4.79. The stock’s fifty day moving average is $21.75 and its two-hundred day moving average is $17.24.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings results on Wednesday, July 29th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The firm had revenue of $71.55 million for the quarter, compared to the consensus estimate of $65.44 million. During the same quarter in the prior year, the company posted ($0.17) EPS. The firm’s revenue was up 21.5% on a year-over-year basis. On average, research analysts predict that Adaptive Biotechnologies Corporation will post -0.4 EPS for the current year.

Analysts Set New Price Targets

ADPT has been the topic of several recent analyst reports. Guggenheim lifted their target price on Adaptive Biotechnologies from $22.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. BTIG Research raised their price target on Adaptive Biotechnologies from $24.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Morgan Stanley lifted their price objective on shares of Adaptive Biotechnologies from $20.00 to $22.00 and gave the company an “equal weight” rating in a research note on Thursday, July 30th. Piper Sandler upped their price objective on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the stock an “overweight” rating in a report on Tuesday, August 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Friday, July 17th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $24.42.

Hedge Funds Weigh In On Adaptive Biotechnologies

Several institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in shares of Adaptive Biotechnologies during the 2nd quarter valued at $324,735,000. Westfield Capital Management Co. LP purchased a new position in shares of Adaptive Biotechnologies during the 4th quarter valued at $65,942,000. Price T Rowe Associates Inc. MD increased its stake in shares of Adaptive Biotechnologies by 303.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock worth $71,252,000 after acquiring an additional 3,299,635 shares during the last quarter. Ameriprise Financial Inc. raised its holdings in shares of Adaptive Biotechnologies by 84.3% during the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock worth $89,337,000 after acquiring an additional 2,731,648 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in shares of Adaptive Biotechnologies by 248.8% during the fourth quarter. Invesco Ltd. now owns 3,107,653 shares of the company’s stock worth $50,468,000 after acquiring an additional 2,216,595 shares in the last quarter. Hedge funds and other institutional investors own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.